Why maximum tolerated dose?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Why maximum tolerated dose?

Published:2019-07-22 Issue:10 Volume:85 Page:2213-2217
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Stampfer Hans G.¹^ORCID,Gabb Genevieve M.²,Dimmitt Simon B.³⁴^ORCID

Affiliation:

1. Division of Psychiatry, Medical School, Faculty of Health and Medical SciencesUniversity of Western Australia Crawley Western Australia

2. Department of General MedicineRoyal Adelaide Hospital Adelaide South Australia

3. Division of Internal Medicine, Medical School, Faculty of Health and Medical SciencesUniversity of Western Australia Crawley Western Australia

4. School of Medicine and Public HealthUniversity of Newcastle Callaghan New South Wales Australia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14032

Reference52 articles.

1. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

2. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

3. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

4. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective

5. Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy;Cell Systems;2024-06

2. Versatile tissue‐injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics;Bioengineering & Translational Medicine;2024-04-15

3. New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and In Vitro Studies;ACS Omega;2024-03-27

4. Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies;Pathology - Research and Practice;2023-11

5. Treatment of evolving cancers will require dynamic decision support;Annals of Oncology;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3